

Barriers to Palliative Care in Cystic Fibrosis (S863)



Elisabeth Dellon, MD MPH, University of North Carolina School of Medicine, Chapel Hill, NC. Mara Hobbler, PhD, University of Washington Medical Center, Seattle, WA. Anna Georgiopoulos, MD, Massachusetts General Hospital, Boston, MA. Elaine Chen, MD, Rush University Medical Center, Chicago, IL. Jessica Goggin, MAS RN, University of California, San Diego, San Diego, CA. Sarah Hempstead, MS, Cystic Fibrosis Foundation, Bethesda, MD. Albert Faro, MD, Cystic Fibrosis Foundation, Bethesda, MD. Dio Kavalieratos, PhD, University of Pittsburgh, Pittsburgh, PA.

Objectives

1. Identify barriers to palliative care for individuals with cystic fibrosis from the perspectives of patients, caregivers, and CF providers.
2. Describe ways to overcome barriers to palliative care in cystic fibrosis.

Original Research Background. In the absence of clear guidelines for palliative care (PC) in cystic fibrosis (CF), little is known about PC provision to individuals with CF and barriers to PC.

Research Objectives. To identify barriers to PC in CF.

Methods. CF care team members (“providers”), adults with CF (“patients”), and family caregivers (“caregivers”) recruited from listservs maintained by the Cystic Fibrosis Foundation completed an online survey about barriers to PC in CF. Responses were analyzed using descriptive statistics.

Results. Surveys were completed by 70 patients, 100 caregivers, and 350 providers. All providers and 96% of patients and caregivers expressed beliefs that PC is valuable for individuals with CF. Nearly half of patients and caregivers recalled knowing someone who received PC, but rarely had personal experience. While 73% of providers reported introducing PC to patients, only 26% of patients and 12% of caregivers recalled learning about PC from providers. From a list of common barriers to PC, all groups identified the same top three: perception that palliative care is only for dying people, lack of access to outpatient PC, and lack of PC training for CF providers. Nearly 1/3 of providers felt patient reluctance to engage in PC conversations is an important barrier, versus 5% of patients and caregivers. Many patients (64%) and caregivers (74%) were not aware of availability of PC specialists, and 19% of providers did not know if PC specialists were available to their patients.

Conclusion. Patients with CF and caregivers report little experience with PC despite a majority of providers reporting they introduce PC to their patients. The most common barriers to PC reflect gaps in

knowledge and provider concerns about patient willingness to engage in PC conversations.

Implications for Research, Policy, or Practice. PC education and tools to promote patient-provider communication may help alleviate barriers to PC in CF.

Non-Surgical Patients with Advanced Gynecologic Cancer Discharged to Subacute Rehabilitation Centers Have Low Rates of Subsequent Chemotherapy (S864)



Nathan Riley, MD, UC San Diego/Scripps Health, San Diego, CA. Camille Cleifton, MD, Kaiser Permanente, Los Angeles, CA. Carolyn Lefkowitz, MD, University of Colorado, Denver, CO.

Objectives

1. Interpret survival data presented as median days after discharge.
2. Interpret significant of results from a univariate analysis.

Original Research Background. Women with advanced gynecologic cancer are often enticed by the promise of additional chemotherapy even when the potential for prolonged life or a cure is slim. Furthermore, many of these patients don’t qualify for additional chemotherapy due to preclusive weakness or medical comorbidities. Despite these observations, they are often discharged from the hospital to skilled rehabilitation centers (SRC) to recuperate the strength to qualify for additional chemotherapy.

Research Objectives. We sought to characterize prognosis and rates of subsequent chemotherapy among non-surgical patients with advanced gynecologic cancer who were discharged to SRC.

Methods. Patients with stage III/IV or recurrent gynecologic malignancy who were admitted to the Kaiser Permanente Southern California health care system and discharged to SRC over a ten-year period were included in this retrospective cohort. Patients who had surgery during their admission or who were enrolled in hospice prior to discharge were excluded. A univariate analysis was performed to identify patient characteristics that might be predictive of receiving future chemotherapy. Statistical significance was ascertained in all analyses through a Fisher’s exact test.

Results. 35 patients met inclusion criteria. The majority were Caucasian (75%), and the median age was 70. Survival after discharge ranged from 5 to 1463 days, with a median survival of 57.5 days. Seven patients (20%) received future chemotherapy after discharge. None of the examined patient or admission factors (age, primary site of malignancy, upfront vs recurrent disease, indication for admission) was predictive of future chemotherapy. Trends toward longer survival